Antithrombotic agents for primary and secondary prevention of cardiovascular events in patients with end-stage renal disease on chronic hemodialysis

Cardiovascular disease (CVD) is common in patients with end-stage renal disease (ESRD) on hemodialysis (HD). However, antithrombotic therapy to prevent CVD increases the risk of bleeding. We aimed to investigate the prevalence of CVD and the practice patterns of antithrombotic agents in patients with ESRD on HD.

Source: Atherosclerosis - February 14, 2020 Category: Cardiology Authors: Oliver K önigsbrügge, Sabine Schmaldienst, Martin Auinger, Renate Klauser-Braun, Matthias Lorenz, Susanne Tabernig, Josef Kletzmayr, Brigitte Enzenberger, Manfred Eigner, Manfred Hecking, Jolanta M. Siller-Matula, Ingrid Pabinger, Marcus Säemann, Cihan Source Type: research